



Ocular Therapeutix™ to Attend American Academy of Ophthalmology Annual Meeting in Chicago, Illinois

October 14, 2014

Amar Sawhney, PhD, CEO, to present at the Ophthalmology Innovation Summit @ AAO

BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 14, 2014-- Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present at the Ophthalmology Innovation Summit (OIS) at AAO on October 16th, 2014 at 11:35 AM. Dr. Sawhney will also sit on the panel *IPOs in Ophthalmology – The Class of 2014 And Beyond* at 4:10 PM. The Ophthalmology Innovation Summit will take place at the Palmer House Hilton in Chicago, IL.

Following the Ophthalmology Innovation Summit, Ocular Therapeutix will exhibit at the American Academy of Ophthalmology (Booth #2770). In addition, several ophthalmologists are scheduled to present data related to Ocular Therapeutix's products and pipeline, including the ReSure® Sealant and its sustained release dexamethasone punctum plugs, during the Annual Meeting.

About the Ophthalmology Innovation Summit

The Ophthalmology Innovation Summit (OIS) was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. OIS addresses key issues – both hurdles and opportunities while showcasing the most promising private ophthalmic companies. For more information, please visit www.ois.net.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery. For more information, please visit www.ocutx.com.

Source: Ocular Therapeutix, Inc.

Investors:

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

bsmith@ocutx.com

or

Burns McClellan on behalf of Ocular Therapeutix

Kimberly Minarovich, 212-213-0006

kminarovich@burnsmc.com

or

Media:

Scott Corning

Vice President of Sales and Marketing

scorning@ocutx.com